(-)-epigallocatechin Clinical Trials

Size	Price	Qty
5mg	USD 147
25mg	USD 297

Clinical Trials

Numerous clinical trials evaluate epigallocatechin and related green tea polyphenols across diverse dermatological, neurodegenerative, and oncological conditions, including acne vulgaris, radiation dermatitis, small cell lung carcinoma, Alzheimer's disease, traumatic brain injury, frailty, and systemic inflammation. Spanning Early Phase 1 through Phase 4, these investigations are sponsored by academic institutions and medical centers, such as Seoul National University Hospital, Charité University, and the University of Rochester. Current recruitment statuses across the dataset encompass completed, recruiting, and suspended studies.

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT06068543	SUSPENDED	Frailty; Inflammation	University of Rochester	2024-10-25	PHASE2
NCT06015022	RECRUITING	Cirrhosis, Liver	University of Texas Southwestern Medical Center	2024-09-01	PHASE2
NCT07697196	NOT_YET_RECRUITING	HPV Infection; HPV Integration; HPV Disease; HPV Genital Infection; HPV Persistence; Low Grade Squamous Intraepithelial Lesions of the Cervix	IRCCS San Raffaele	2026-07
NCT07149506	ENROLLING_BY_INVITATION	Radiation Dermatitis Acute; Radiation Dermatitis; Fibrosis; Skin	CARLOS FRANCISCO SAAVEDRA GARCIA	2025-09-01	PHASE3
NCT05364008	ACTIVE_NOT_RECRUITING	Leiomyoma, Uterine	Yale University	2023-01-05	PHASE3
NCT05409872	COMPLETED	Leiomyoma, Uterine	Universita di Verona	2022-09-15
NCT06398405	UNKNOWN	Esophageal Cancer; Dysphagia, Esophageal; Epigallocatechin Gallate	Shandong Cancer Hospital and Institute	2024-04-22	PHASE2
NCT05195918	COMPLETED	Idiopathic Pulmonary Fibrosis	Hal Chapman	2023-08-24	PHASE1
NCT07725900	COMPLETED	Hyperpigmentation; Dry Skin; Erythema	Naniek Widyaningrum	2025-12-01	PHASE2; PHASE3
NCT05448365	RECRUITING	Uterine Fibroids; D-chiro-inositol; Inositol; Epigallocatechin Gallate; Vitamin D; Vitamin B6	Lo.Li.Pharma s.r.l	2022-07-01
NCT06285357	RECRUITING	HPV Infection	Lo.Li.Pharma s.r.l	2024-02-19
NCT05811403	COMPLETED	Irreversible Pulpitis	Cairo University	2023-07-01
NCT06531863	RECRUITING	Mood Disturbance	Auburn University	2024-09-30	EARLY_PHASE1
NCT06524609	UNKNOWN	Chemotherapy-induced Peripheral Neuropathy	Han Xi Zhao	2023-11-30	PHASE1; PHASE2
NCT05988788	COMPLETED	Necrotic Pulp	Cairo University	2023-10-01
NCT02891538	COMPLETED	Colon Cancer	The University of Texas Health Science Center at San Antonio	2017-01-31	EARLY_PHASE1
NCT04553666	COMPLETED	Frailty; Inflammation	University of Rochester	2021-04-28	PHASE2
NCT01744587	COMPLETED	NPC	National Health Research Institutes, Taiwan	2013-04
NCT05625308	COMPLETED	Papilloma; Cervix Lesion	Lo.Li.Pharma s.r.l	2022-07-01
NCT05116098	UNKNOWN	Tuberculosis	Ministry of Health, Saudi Arabia	2021-11-30	PHASE1
NCT02577393	UNKNOWN	Lung Neoplasms; Esophagitis; Prevention & Control; Epigallocatechin Gallate	Shandong Cancer Hospital and Institute	2015-04	PHASE2
NCT05349903	COMPLETED	Appetitive Behavior; Obesity; Diabetes Mellitus, Type 2	Purdue University	2021-11-10
NCT04177693	COMPLETED	Uterine Fibroids	Yale University	2020-11-24	PHASE1
NCT03883880	TERMINATED	Diet, Food Choice, Taste	Purdue University	2019-01-05
NCT02887950	TERMINATED	Overweight	Fondazione IRCCS Policlinico San Matteo di Pavia	2016-09
NCT02580279	UNKNOWN	Breast Neoplasms; Dermatitis; Prevention & Control; Epigallocatechin Gallate	Shandong Cancer Hospital and Institute	2014-12	PHASE2
NCT03928847	COMPLETED	Idiopathic Pulmonary Fibrosis	Hal Chapman	2017-12-01	EARLY_PHASE1
NCT03740295	COMPLETED	Multiple Sclerosis	Fundación Universidad Católica de Valencia San Vicente Mártir	2018-10-05	PHASE2
NCT01183767	COMPLETED	Duchenne Muscular Dystrophy	Charite University, Berlin, Germany	2010-12-30	PHASE2; PHASE3
NCT02015312	COMPLETED	Light Chain (AL) Amyloidosis; Cardiac Involvement	Florian Michel	2013-04	PHASE2
NCT03194620	COMPLETED	Healthy	University of California, Davis	2016-08
NCT02558933	COMPLETED	Fetal Alcohol Syndrome (FAS)	Fundacion Clinic per a la Recerca Biomédica	2016-03
NCT01511263	TERMINATED	Primary Amyloidosis of Light Chain Type	Fondazione IRCCS Policlinico San Matteo di Pavia	2012-01	PHASE2
NCT00799890	COMPLETED	Multiple Sclerosis	Friedemann Paul	2009-05	PHASE2; PHASE3
NCT03199430	COMPLETED	EGCG Influence on Catecholamine Metabolism	Swansea University	2015-09	PHASE4
NCT00434499	WITHDRAWN	Hypertension; Obesity; Type 2 Diabetes; Insulin Resistance	University of Maryland, Baltimore	2007-02	PHASE2
NCT02731495	COMPLETED	Traumatic Brain Injury	National Nutrition and Food Technology Institute	2015-03	PHASE2; PHASE3
NCT01357681	COMPLETED	Huntington Disease	Charite University, Berlin, Germany	2011-09	PHASE2
NCT00951834	COMPLETED	Alzheimer's Disease	Charite University, Berlin, Germany	2009-10	PHASE2; PHASE3
NCT02147041	UNKNOWN	Diabetes Mellitus; Hyperlipidemia	Taipei City Hospital	2012-05	PHASE2; PHASE3
NCT01699711	COMPLETED	Down Syndrome (DS)	Parc de Salut Mar	2012-02	PHASE2
NCT00951964	COMPLETED	Epidermolysis Bullosa Dystrophica	Centre Hospitalier Universitaire de Nice	2010-10	PHASE2
NCT00525668	COMPLETED	Relapsing-remitting Multiple Sclerosis	Charite University, Berlin, Germany	2007-09	PHASE1; PHASE2
NCT01394796	COMPLETED	Down Syndrome	Parc de Salut Mar	2010-05	PHASE2
NCT00981292	COMPLETED	Cognitive Function; Mood	Northumbria University	2009-08	PHASE4
NCT01687556	COMPLETED	Acne Vulgaris	Seoul National University Hospital	2005-07
NCT00153790	COMPLETED	Weight Loss	The Cooper Institute	2005-04	PHASE1
NCT00476138	UNKNOWN	Primary Open Angle Glaucoma; Ocular Hypertension	Catholic University of the Sacred Heart	2006-11	PHASE1; PHASE2

(data from https://clinicaltrials.gov, updated on 2026-06-26)

Check the (-)-epigallocatechin product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.

Compliance for Clinical Use

Mechanism and Biochemical Profile

(-)-Epigallocatechin binds key cellular targets and modulates oxidative stress pathways, thereby blocking downstream pro-inflammatory kinase signaling and oncogenic transcription factors. This inhibition reduces cellular proliferation and inflammatory output, providing a mechanistic basis for its clinical investigation in conditions such as acne vulgaris, radiation dermatitis, small cell lung carcinoma, and chronic inflammation.

Appendix RUO and cGMP Quality Standards

Quality Dimension	RUO (Research Use Only)	cGMP (Current Good Manufacturing Practice)
Clinical Applicability	Prohibited in human clinical trials or medical diagnostics.	Mandatory for human clinical trials (Phase I–III) and therapies.
Regulatory Status	Non-regulated grade; exempt from drug manufacturing laws.	Legally enforced by health authorities (e.g., FDA, EMA, NMPA).
Facility Environment	Unclassified analytical or research laboratories.	Validated Cleanrooms (ISO Class 5–8) with continuous monitoring.
Quality Control	Basic purity and activity testing.	Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma).
Process Validation	Basic equipment calibration; no process validation required.	Full qualification (IQ/OQ/PQ) and complete batch records.
Quality Assurance	Vendor self-declared without required formal QMS.	Mandatory QA/QC unit, Change Control, CAPA, and vendor audits.
Regulatory Impact	High risk of IND rejection if used as a critical raw material.	Required for IND/NDA filings, supported by Drug Master Files (DMF).

Footnotes

Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).